Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com
StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note published on Monday. The firm issued a hold rating on the biotechnology company’s stock. Brainstorm Cell Therapeutics Stock Performance Shares of NASDAQ:BCLI opened at $1.27 on Monday. The company’s fifty day moving average is $1.25 and its two-hundred […]
StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note published on Monday. The firm issued a hold rating on the biotechnology company’s stock. Brainstorm Cell Therapeutics Stock Performance Shares of NASDAQ:BCLI opened at $1.27 on Monday. The company’s fifty day moving average is $1.25 and its two-hundred […]
